3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Not yet recruiting
1
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
8
Recurrence
1
Immunoglobulin Light-chain Amyloidosis
1
Interventions
Dexamethasone
27
Melphalan
22
Cyclophosphamide
15
Peripheral Blood Stem Cell Transplantation
14
Filgrastim
13
Bortezomib
12
Calcium Dobesilate
9
Lenalidomide
7
fludarabine phosphate
6
Whole-Body Irradiation
5
Mycophenolic Acid
5
Cyclosporine
5
Thalidomide
4
Interferon-alpha
4
Etoposide
4
Busulfan
4
miridesap
3
dexamethasone acetate
3
Radiotherapy
3
Epoetin Alfa
3
Doxycycline
3
Darbepoetin alfa
3
Carboplatin
3
pomalidomide
2
liposomal amphotericin B
2
ixazomib
2
daratumumab
2
birtamimab
2
Thiotepa
2
Tacrolimus
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Immunoglobulin Light-chain Amyloidosis
×
belantamab mafodotin
×
Clear all
NCT04617925
2025-09-05
EMN27
European Myeloma Network B.V.
Phase 2
Completed
35 enrolled